Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. La Jolla Pharmaceutical Company. (LJPC) Message Board

La Jolla Pharma (LJPC) Galectin-3 Inhibitor Positive Top-Line

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 66
Posted On: 03/11/2014 6:52:05 AM
Posted By: riddock57

http://pennyomega.com/img/ljpc.jpg La Jolla Pharmaceutical Co. (LJPC)


The main function of the kidneys is to remove wastes and excess water from the body.


Did you know that a person can lose up to 90% of their kidney function before experiencing any symptoms?


Chronic kidney disease is the slow loss of kidney function over time. It slowly gets worse over time. In the early stages, there may be no symptoms. The loss of function usually takes months or years to occur. It may be so slow that symptoms do not appear until kidney function is less than one-tenth of normal.


The final stage of chronic kidney disease is called end-stage renal disease. At this stage, the kidneys are no longer able to remove enough wastes and excess fluids from the body. The patient needs dialysis or a kidney transplant.


Chronic kidney disease and end-stage renal disease affect more than 2 out of every 1,000 people in the United States.


The two main causes of chronic kidney disease are diabetes and high blood pressure, which are responsible for up to two-thirds of the cases.


LJPC reported positive top-line results from its Phase 2 clinical trial of GCS-100 in chronic kidney disease. The trial met its primary efficacy endpoint of a statistically significant improvement in kidney function. LJPC 's GCS-100 was well-tolerated


LJPC' s GCS-100 is a high molecular weight, complex polysaccharide that inhibits galectin-3, a molecule believed to play a central role in tissue fibrosis, or scarring. GCS-100 currently is in Phase 2 clinical development for chronic kidney disease and also has been shown to be therapeutically active in preclinical models of other diseases where tissue fibrosis plays a central role, such as nonalcoholic steatohepatitis.


http://pennyomega.com/img/ljpc_chart.png


LJPC is focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer.


More about La Jolla Pharmaceutical Co. (LJPC) at www.ljpc.com .


**


http://pennyomega.com/img/crwe_logo.jpg Crown Equity Holdings Inc. (CRWE)


CRWE is currently developing its CRWE Network ( CRWE-PR.com ), a social networking service compatible with both, the mobile and desktop web platform, that is designed to target all the communities in the U.S. and Canada, which business model is based on selling advertising to local businesses.


CRWE-PR is continuing to increase its foot print community targeted publications of websites with local news, information and business directory delivery.


The CRWE Network has surpassed the 100th community website, and includes coverage of the greater state of California, Northern and Southern Nevada and 9 provinces in Canada


http://pennyomega.com/img/mar10crwe.png


CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet


More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com


**


http://pennyomega.com/img/sfl.jpg Ship Finance International Limited (SFL)


SFL reported the settlement of a claim relating to four Handysize dry bulk carriers which were redelivered to the company in 2012, before the final maturity of their charters.


According to the company, a significant portion of the settlement amount has been paid to SFL in cash already, with the remaining amount to be paid in installments over the next three quarters. SFL expects to book a gain of approximately $25 million relating to the settlement.


SFL also announced the agreement to acquire two 5,800 teu post-panamax container vessels built in 2001/2002 in combination with long-term charters.


The vessels are expected to be delivered to SFL over the course of the next few weeks, and the annual EBITDA contribution is estimated to be approximately $5.5 million on average during the charter period. The charters include a purchase option with profit share after 5 years.


http://pennyomega.com/img/sfl_chart.png


SFL is a major vessel owning company. Its fleet is one of the largest in the world and the Company has a substantial portfolio of long term fixed charters with an average tenor of approximately 10 years. Stability in both charter revenues and operating costs supports SFL 's long term distribution capacity.


More about Ship Finance International Limited (SFL) at www.shipfinance.org


**


Read Full Disclaimer at www.pennyomega.com/disclaimer



(0)
(0)




La Jolla Pharmaceutical Company. (LJPC) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us